Abstract: Methods of enhancing efficiency of downstream chromatography steps for purification of proteins comprising: (a) passing a composition comprising a polypeptide of interest and various contaminants through an ion exchange membrane, wherein the polypeptide and the membrane have opposite charge, at operating conditions comprised of a buffer having a pH sufficiently distinct from the pi of the polypeptide to enhance the charge of the polypeptide and a low ionic strength effective to prevent the shielding of charges by buffer ions, which cause the membrane to bind the polypeptide and at least one contaminant, (b) overloading the ion exchange membrane such that at least one contaminant remains bound to the membrane while the polypeptide of interest is primarily in the effluent; (c) collecting the effluent from the ion exchange membrane comprising the polypeptide of interest; (d) subjecting the membrane effluent comprising the polypeptide of interest to a purification step of similar charge as the previous membrane,
Type:
Application
Filed:
March 1, 2024
Publication date:
July 25, 2024
Applicant:
Genentech, Inc.
Inventors:
Jerome Joseph BILL, JR., Arick Michael BROWN, Christopher John DOWD, Brooke Ellen THAYER
Abstract: The invention relates to a new process for the purification of oligonucleotides which comprises the removal of the acid labile 5?hydroxy protecting group at the 5?-O-oligonucleotide terminus of the oligonucleotide by way of tangential flow filtration with an acidic buffer solution. The process requires less steps and allows a higher degree of automation.
Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins where the TI host cells are also subjected to transposon-mediated genomic integration of one or more exogenous nucleic acids, as well as methods of producing and using said combined transposon-mediated genomic integration and TI host cells.
Type:
Application
Filed:
November 15, 2023
Publication date:
July 18, 2024
Applicant:
Genentech, Inc.
Inventors:
Amy Shen, Gavin Christian Barnard, Shuet Ming Yip
Abstract: The presently disclosed subject matter relates to combinatorial vector cloning and transfection strategies for the generation of targeted integration host cells suitable for the expression of recombinant proteins, as well as targeted integration host cells generated by said strategies and compositions comprising said targeted integration host cells.
Abstract: The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein Z1, Z2, R3-R8, RA, ring A, and n have the meanings described herein, and compositions containing such compounds and methods for using such compounds and compositions for the treatment of pain.
Type:
Application
Filed:
February 22, 2024
Publication date:
July 18, 2024
Applicant:
Genentech, Inc.
Inventors:
Steven John MCKERRALL, Daniel Fred ORTWINE, Philippe BERGERON, Ramsay BEVERIDGE, Elise GHIRO, Kwong Wah LAI, Guqin SHI
Abstract: The invention provides anti-kallikrein-related peptidase 5 (KLK5) antibodies and methods of using the same.
Type:
Grant
Filed:
November 17, 2020
Date of Patent:
July 16, 2024
Assignee:
Genentech, Inc.
Inventors:
Cecilia P. C. Chiu, Hilda Y. Hernandez-Barry, David B. Iaea, Moulay Hicham Alaoui-Ismaili, James T. Koerber, Wei Yu Lin, Kelly Loyet, Yonglian Sun, Benjamin T. Walters, Jawahar Sudhamsu
Abstract: The invention provides compounds of formulae I, II, IIa, and III: and pharmaceutically acceptable salts thereof, as well as compositions containing such compounds and methods for using such compounds and compositions.
Type:
Application
Filed:
February 22, 2024
Publication date:
July 11, 2024
Applicant:
Genentech, Inc.
Inventors:
Marc KSCHONSAK, Steven John MCKERRALL, Daniel Fred ORTWINE, Jian Mehr-Dean PAYANDEH, Benjamin Douglas SELLERS, John C. TELLIS, Matthew VOLGRAF, Philippe BERGERON, Claudio CIFERRI, Peter Scott DRAGOVICH
Abstract: The application describes a method of treating chronic obstructive pulmonary disease (COPD) in a patient comprising administering 476 mg of an ST2 antagonist to the patient on Day 1 of a treatment period. The application also describes methods of treating or preventing frequency of moderate to severe exacerbations in a patient having COPD comprising administering an effective amount of an ST2 antagonist to achieve a clinical improvement of at least 10%, at least 20%, at least 21%, at least 22%, at least 25%, at least 30%, at least 35%, at least 40% or at least 45% annualized exacerbation rate reduction than standard of care (SOC).
Type:
Application
Filed:
December 4, 2023
Publication date:
July 11, 2024
Applicant:
Genentech, Inc.
Inventors:
Michele Anne Grimbaldeston, Divya Mohan, Ahmed Yousuf, Christopher Brightling, Dorothy Sze-Wing Cheung, David Fong Choy
Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
Type:
Grant
Filed:
February 9, 2021
Date of Patent:
July 9, 2024
Assignee:
Genentech, Inc.
Inventors:
Justin Scheer, Whitney Shatz, Domingos Ng
Abstract: The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
Type:
Grant
Filed:
October 12, 2023
Date of Patent:
July 9, 2024
Assignee:
Genentech, Inc.
Inventors:
Ryan Patrick Owen, Ahmar Iqbal, Robert A. Wood
Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
Type:
Grant
Filed:
October 29, 2021
Date of Patent:
July 9, 2024
Assignee:
Genentech, Inc.
Inventors:
Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
Abstract: The present disclosure relates to techniques for segmenting objects within medical images using a deep learning network that is localized with object detection based on a derived contrast mechanism. Particularly, aspects are directed to localizing an object of interest within a first medical image having a first characteristic, projecting a bounding box or segmentation mask of the object of interest onto a second medical image having a second characteristic to define a portion of the second medical image, and inputting the portion of the second medical image into a deep learning model that is constructed as a detector using a weighted loss function capable of segmenting the portion of the second medical image and generating a segmentation boundary around the object of interest. The segmentation boundary may be used to calculate a volume of the object of interest for determining a diagnosis and/or a prognosis of a subject.
Type:
Application
Filed:
March 19, 2024
Publication date:
July 4, 2024
Applicant:
Genentech, Inc
Inventors:
Luke XIE, Kai Henrick Barck, Omid Bazgir
Abstract: Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support.
Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
Type:
Application
Filed:
September 1, 2023
Publication date:
June 27, 2024
Applicant:
Genentech, Inc.
Inventors:
Michael ADLER, Ulla GRAUSCHOPF, Hanns-Christian MAHLER, Oliver Boris STAUCH
Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
Abstract: Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.
Type:
Grant
Filed:
November 11, 2021
Date of Patent:
June 25, 2024
Assignee:
GENENTECH, INC
Inventors:
Marie Evangelista, Mark Andrew Merchant, Jennifer Lee Schutzman, Ting-Kun Mark Lin, Stephanie Royer Joo, Sandhya Vinayak Mandlekar, Stuart G. Lutzker
Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
Type:
Grant
Filed:
April 14, 2021
Date of Patent:
June 25, 2024
Assignee:
Genentech, Inc.
Inventors:
Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu